The Knight ADRC has supported many investigators at Washington University and at other institutions over the years. We wish to avoid the situation where two investigators study the same research question to avoid duplication of effort and potential conflict. To determine if your topic has already been studied with our resources, please search our database. If you find that your topic or a related topic has been submitted, you may wish to contact the investigator to inquire about their findings to determine how you might proceed. You may wish to collaborate or modify your request to avoid overlap. The results below reflect requests made since online requests have been accepted. As such, not all fields will have data as certain information, such as aims, were not collected until recently. If an entry has been assigned an ID number (e.g. T1004), the full request has been submitted and is either approved, disapproved or in process. If an entry has no ID number, then it represents a submission that has not yet been reviewed. Search terms are applied across an entire requests application including variables not displayed below. A more specific, detailed search may yield better results depending upon your needs.
Search Terms:
Investigator: Ruiwen Zhou
Project Title: Dynamic Multimodal Prediction of Alzheimer’s Disease Progression Using Longitudinal Data with Missing-Modality Generative Modeling
Date: May 6, 2026 at 11:29 am
Request ID: D2628
Aim 1: Develop a Longitudinal Multimodal Deep Learning Framework for Dynamic Prediction of Alzheimer’s Disease Progression
Aim 2: Design a Generative Missing-Modality Framework for Longitudinal Multimodal Alzheimer’s Disease Data
Aim 3: Identify Longitudinal Multimodal Biomarkers and Disease Trajectories Associated with Alzheimer’s Disease Progression
Aim 4:
Investigator: Shubham Chandra
Project Title: Virtual Spectral Decomposition of Multiplexed Plasma Biomarkers for Multi-Class Dementia Routing: Extending a Blood-Based Alzheimer’s Disease Signature Framework to FTD, DLB, and Vascular Dementia
Date: May 4, 2026 at 7:56 am
Request ID: D2627
Aim 1: Validate a 4-biomarker VSD framework (pT217, Aβ42/40, NfL, GFAP) developed on ADNI in the Knight ADRC cohort to assess cross-cohort generalizability of AD disease signature coupling patterns and exclusion logic against amyloid PET ground truth.
Aim 2: Identify candidate plasma proteins from the NULISAseq CNS panel that provide differential signal across AD, DLB, FTD, and PD diagnostic groups, to define new VSD channel weights and dendritic branch terminals for multi-class dementia routing.
Aim 3: Characterize biomarker coupling structure within the non-AD neurodegeneration subgroup to determine whether VSD channel activation patterns can discriminate FTD from DLB from vascular contributions using expanded protein panels.
Aim 4: Evaluate longitudinal stability of VSD-derived disease route assignments across repeated plasma draws to assess whether routing classifications track with clinical progression or remain static at baseline assignment.
Investigator: Carlos Cruchaga
Project Title: Transcriptomics and multiomic predictive models in AD and ADRD
Date: May 4, 2026 at 7:21 am
Request ID: D2626
Aim 1: 1. To benchmark the blood circRNA and proteomic models in predicting AD compared to MS tau analytes in CSF and plasma and determine on how the overlap with other biomarkers.
Aim 2: Pathways and cell type enrichment of the transcripts and proteins associated with AD phenotypes (risk, onset, progression) or endophenotypes (AD biomarker levels).
Aim 3: Integrating the MS proteomic data with the rest of the omic data to further refine the AI-derived model.
Aim 4:
Investigator: Pieter Jelle Visser and Willemijn Jansen
Project Title: Early diagnosis of Alzheimer’s disease: insight into p-tau217 as a new blood-based biomarker
Date: May 1, 2026 at 4:15 am
Request ID: D2625
Aim 1: We aim to gain more insight into the prevalence of plasma p-tau217 abnormality across the continuum of AD (NC/SCD/MCI/AD), dependent on age, APOEe4 status, sex, education level, comorbidities, and diagnosis.
Aim 2: We aim to investigate differences in the prevalence of plasma p-tau217 positivity in and between different ethnic groups.
Aim 3: We aim to investigate how plasma p-tau217 levels relate to cognitive function and decline over time.
Aim 4: We aim to compare the predictive ability of plasma p-tau217 with other plasma, PET and CSF biomarkers, such as other p-tau species, NFL and GFAP.
Investigator: Guoyan Zhao
Project Title: Elucidating shared vascular mechanisms of neurodegeneration through uniform single-nucleus RNA transcriptomic analysis
Date: April 28, 2026 at 12:09 am
Request ID: D2624
Aim 1: Delineate vascular cell-specific transcriptomic changes across five NDDs and five brain regions
Aim 2: Identify candidate drugs through consensus in silico screening.
Aim 3:
Aim 4:
Investigator: Suprateek Kundu
Project Title: Multimodal Biomarker Approaches for Risk Stratification and Screening in Alzheimer’s Disease
Date: April 25, 2026 at 1:09 pm
Request ID: D2623
Aim 1: To integrate baseline blood-based biomarkers with regional longitudinal structural brain atrophy changes, to predict future cognitive decline in cognitively unimpaired individuals, and infer significant interactions between regional neurodegeneration and p-tau217.
Aim 2: To integrate baseline blood-based biomarkers with regional longitudinal white matter hyperintensity (WMH) changes, to predict future cognitive decline in cognitively unimpaired individuals, and infer significant interactions between regional WMH and p-tau217.
Aim 3: To forecast future neurodegeneration in cognitively unimpaired individuals, by predicting long term brain atrophy and white matter hyperintensity changes based on longitudinal imaging data from earlier visits.
Aim 4:
Investigator: Katherine Goulden
Project Title: Neuropsychological Differences Between Early Neurodegenerative Disease and Suspected Functional Cognitive Disorder in Latino and Non-Latino Older Adults
Date: April 25, 2026 at 12:38 pm
Request ID: D2622
Aim 1: Characterize neuropsychological performance patterns across individuals with self-reported cognitive concerns and normal cognition as a group with suspected Functional Cognitve Disorder, biomarker-validated MCI and healthy controls.
Aim 2: . Identify neuropsychological indicators that distinguish FCD from neurodegenerative MCI. These are: inconsistent patterns of the Everyday Cognition self and study partner reports, measuring discrepancy between subjective report and objective performance neuropsychological tests.
Aim 3: Examine whether neuropsychological patterns differ between Hispanic/Latino and non‑Hispanic groups. This supports culturally valid diagnostic frameworks by checking differential performance profiles and accounting for language or education‑related testing artifacts and cultural differences.
Aim 4:
Investigator: Shant Afarian
Project Title: Blood-Brain Barrier Transport of Plasma Proteins in Cerebral Small Vessel Disease
Date: April 25, 2026 at 11:25 am
Request ID: D2621
Aim 1: Identify plasma proteins that show evidence of blood-brain barrier transport.
Aim 2: Determine whether CSVD burden is associated with altered BBB transport.
Aim 3: Identify structural and genetic determinants of altered BBB transport in CSVD.
Aim 4:
Investigator: Tae Youn Kwon
Project Title: External Validation of MRI-Derived Regional Tau Prediction and Its Clinical Utility for Tau Subtype and Cognitive Decline Analysis
Date: April 19, 2026 at 12:06 am
Request ID: D2620
Aim 1: To validate the performance of an MRI-based regional tau prediction model in an independent FTP tau-PET cohort and determine its generalizability across key demographic and disease-related subgroups.
Aim 2: To characterize spatial heterogeneity of predicted tau deposition by identifying tau subtypes from MRI-derived regional estimates and comparing them with subtype patterns derived from observed tau-PET.
Aim 3: To assess the relationship of MRI-predicted tau burden and subtype membership with baseline cognitive impairment and longitudinal cognitive decline in individuals across the Alzheimer’s disease spectrum.
Aim 4:
Investigator: Donohue
Project Title: Assessing design artifacts and added value of plasma ptau217 clocks
Date: April 17, 2026 at 11:16 am
Request ID: D2619
Aim 1: Assessing design artifacts in studies of plasma ptau217 clocks
Aim 2: Assessing added value of plasma ptau217 clocks
Aim 3:
Aim 4: